Potential near-and mid-term value drivers

  • Sustained M&A & in-licensing to build critical mass in oncology
  • Cantrixil – initiation of Phase 2
  • Docetaxel micellar – Phase 1b completion
  • Apealea® – initiation of additional US pivotal studies by Elevar; partnering in key territories; potential for initial royalties
  • XR-17™ technology platform – enhancement
  • Animal Health assets – divestment or partnering agreements
  • 2 nd most common

    Cancer is the 2nd most common cause of death1

  • 18 million people

    18 million people were diagnosed with cancer in 20181

  • USD 240 billion

    The total expenditure on oncology worldwide in 2023 is estimated to be USD 240 billion2

1 World Cancer Research Fund
2 Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science.